Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Chief Worried About Innovation, Spanish Debts

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer's chairman, Marijn Dekkers, calls for a greater appreciation of pharmaceutical inventors and brands, as the diversified Big Pharma reported group sales up 4% in 2011, and profits up 90% on lower charges.

You may also be interested in...

Europe’s Pharma Industry Expects Little Relief In 2013 After Bruising 2012

Europe was a tough market for the drugs industry in 2012, with governments imposing austerity measures and price cuts on medicines that hit companies hard. The euro survived, preventing further disruption of the marketplace, but little respite is expected in the next 12 months for patients and companies alike from clampdowns on health care spending in general, and medicines reimbursement in particular.

Radiotherapeutics Market Snapshot: This Sector Is Getting Hot

The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.

Philogen Ties Up With Actinium To Develop Cancer-Targeted Radioisotope-Labeled Antibodies

Italy's Philogen is to evaluate alpha-particle emitting actinium as the cytotoxic payload for its angiogenesis-targeted monoclonal antibody platform, under a collaboration with New Jersey-based Actinium Pharmaceuticals.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts